Acción TH THERATECHNOLOGIES INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Theratechnologies Inc.

Acciones

TH

CA88338H7040

Mercado cerrado - Toronto S.E.
Otros sitios de cotización
 22:00:00 26/04/2024 		Varia. Cinco días. Varia. 1 de enero.
1,8 CAD 0,00 % Gráfico intradía de Theratechnologies Inc. -0,55 % -15,89 %
10/04 Actualización sobre Theratechnologies; baja más de un 5% en TSX al reducirse la pérdida neta del 1T y a la espera de la decisión de la FDA MT
10/04 Theratechnologies sube cerca de un 6% en las operaciones previas a la comercialización en EE.UU. al reducirse la pérdida neta del 1T y acelerar el ensayo de fase 1 de un fármaco contra el cáncer de ovario MT

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug
Theratechnologies: Fiscal Q1 Earnings Snapshot
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024
North American Morning Briefing : Traders Await -2-
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform
Theratechnologies Appoints Elina Tea to its Board of Directors
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción TH
  4. Noticias Theratechnologies Inc.
  5. Otros idiomas